Literature DB >> 7942728

Erythromycin as a prokinetic agent: a prospective, randomized, controlled study of efficacy in nasoenteric tube placement.

M A Stern1, D C Wolf.   

Abstract

OBJECTIVES: Erythromycin, a macrolide antibiotic, has been shown to mimic the effects of the polypeptide motilin in the gastrointestinal tract. To determine whether erythromycin ethylsuccinate elixir would facilitate the transpyloric passage of a standard nasoenteric feeding tube once the tube was placed into the stomach, 20 patients were randomized to receive erythromycin or standard therapy.
METHODS: Twenty patients (ages 45-78), mean age 63 yr, all male, had 43-inch nasoenteric tubes placed and were randomized to receive erythromycin ethylsuccinate elixir (400 mg/5 ml per os every 8 h for three doses) through the feeding tube or to receive standard therapy that involved no drug intervention.
RESULTS: Three placements resulted in immediate transpyloric passage. This represented 3/21 (14%) with immediate passage. One patient dropped out after initial tube placement. The remaining 17 patients had initial tube placement in the stomach; of these, eight were randomized to receive erythromycin and nine to receive standard therapy. Six of the eight nasoenteric tubes in the erythromycin group achieved transpyloric passage in 1 day. Zero of the nine nasoenteric tubes in the standard therapy group achieved transpyloric passage in 1 day (p = 0.0023, Fisher's exact test).
CONCLUSION: This study demonstrates that erythromycin ethylsuccinate elixir improves the success of transpyloric feeding tube passage in 1 day and is superior to the standard therapy, which consists of no drug intervention.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7942728

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  10 in total

1.  Randomised controlled study of oral erythromycin for treatment of gastrointestinal dysmotility in preterm infants.

Authors:  P C Ng; K W So; K S Fung; C H Lee; T F Fok; E Wong; W Wong; K L Cheung; A F Cheng
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-05       Impact factor: 5.747

2.  Chronic Intestinal Pseudo-obstruction.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  1999-06

Review 3.  Enteral nutrition and the critically ill.

Authors:  S A Shikora; A M Ogawa
Journal:  Postgrad Med J       Date:  1996-07       Impact factor: 2.401

4.  Gastric and Postpyloric Total Enteral Nutrition.

Authors:  Souheil G Abou-Assi; Vikash Khurana; Mitchell L Schubert
Journal:  Curr Treat Options Gastroenterol       Date:  2005-04

Review 5.  Gastroparesis--current concepts and considerations.

Authors:  William L Hasler
Journal:  Medscape J Med       Date:  2008-01-23

Review 6.  Post-pyloric feeding.

Authors:  Eva Niv; Zvi Fireman; Nachum Vaisman
Journal:  World J Gastroenterol       Date:  2009-03-21       Impact factor: 5.742

Review 7.  Clinical uses of gut peptides.

Authors:  J Geoghegan; T N Pappas
Journal:  Ann Surg       Date:  1997-02       Impact factor: 12.969

Review 8.  Metoclopramide for post-pyloric placement of naso-enteral feeding tubes.

Authors:  Cristiane Costa Reis da Silva; Cathy Bennett; Humberto Saconato; Álvaro N Atallah
Journal:  Cochrane Database Syst Rev       Date:  2015-01-07

Review 9.  Erythromycin for Promoting the Postpyloric Placement of Feeding Tubes: A Systematic Review and Meta-Analysis.

Authors:  Qing-Jun Jiang; Cai-Feng Jiang; Qi-Tong Chen; Jian Shi; Bin Shi
Journal:  Gastroenterol Res Pract       Date:  2018-04-03       Impact factor: 2.260

10.  Erythromycin versus metoclopramide for post-pyloric spiral nasoenteric tube placement: a randomized non-inferiority trial.

Authors:  Bei Hu; Xin Ouyang; Liming Lei; Cheng Sun; Ruibin Chi; Jian Guo; Wenlong Guo; Yanlin Zhang; Yong Li; Daoyong Huang; Huafeng Sun; Zhiqiang Nie; Jieyang Yu; Yuan Zhou; Hao Wang; Jinhe Zhang; Chunbo Chen
Journal:  Intensive Care Med       Date:  2018-11-21       Impact factor: 17.440

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.